[SCHEDULE 13D/A] ArriVent BioPharma, Inc. SEC Filing
OrbiMed filed Amendment No. 1 to its Schedule 13D regarding ArriVent BioPharma common stock to report a change in beneficial ownership after an increase in shares outstanding. The amendment discloses an aggregate beneficial ownership of 3,027,328 shares, representing approximately 7.5% of the 40,568,944 outstanding shares reported in ArriVent's Quarterly Report. The filing clarifies that OrbiMed Private Investments VIII, LP and OrbiMed Asia Partners IV, L.P. each hold 1,513,664 shares (about 3.7% each) and that OrbiMed Advisors, GP VIII, OAP GP IV and Advisors IV have shared or sole voting and dispositive power over those positions.
The Reporting Persons state the shares were acquired for investment purposes and not to obtain control, and confirm they have no current plans to pursue extraordinary transactions or board changes. The filing also summarizes an Amended and Restated Investors' Rights Agreement that provides demand registration rights (requests for S-1 registrations exceeding $20 million), Form S-3 registration rights (thresholds including $5 million and certain percentage holders) and piggyback registration rights, and notes that director Carl L. Gordon is a board member and may receive equity awards subject to transfer obligations to the OrbiMed entities.
OrbiMed ha presentato l'Amendment No. 1 al proprio Schedule 13D relativo alle azioni ordinarie di ArriVent BioPharma per segnalare una variazione nella proprietà effettiva a seguito dell'aumento delle azioni in circolazione. L'emendamento dichiara una titolarità aggregata di 3,027,328 azioni, pari a circa 7.5% delle 40,568,944 azioni in circolazione indicate nel Quarterly Report di ArriVent. Il documento chiarisce che OrbiMed Private Investments VIII, LP e OrbiMed Asia Partners IV, L.P. detengono ciascuna 1,513,664 azioni (circa il 3,7% ciascuna) e che OrbiMed Advisors, GP VIII, OAP GP IV e Advisors IV esercitano congiuntamente o individualmente potere di voto e di disposizione su tali posizioni.
I dichiaranti affermano che le azioni sono state acquistate per fini di investimento e non per acquisire il controllo, e confermano di non avere piani attuali per operazioni straordinarie o cambiamenti nel consiglio di amministrazione. L'atto riassume inoltre un Amended and Restated Investors' Rights Agreement che prevede diritti di registrazione su richiesta (richieste di registrazione S-1 superiori a $20 million), diritti di registrazione su Form S-3 (soglie che includono $5 million e detentori con determinate percentuali) e diritti di registrazione piggyback, e nota che il direttore Carl L. Gordon è membro del consiglio e potrà ricevere assegnazioni azionarie soggette a obblighi di trasferimento verso le entità OrbiMed.
OrbiMed presentó la Enmienda nº 1 a su Schedule 13D relativa a las acciones ordinarias de ArriVent BioPharma para informar un cambio en la propiedad efectiva tras un aumento en las acciones en circulación. La enmienda declara una participación agregada de 3,027,328 acciones, que representa aproximadamente el 7.5% de las 40,568,944 acciones en circulación informadas en el Quarterly Report de ArriVent. El documento aclara que OrbiMed Private Investments VIII, LP y OrbiMed Asia Partners IV, L.P. poseen cada una 1,513,664 acciones (aprox. 3,7% cada una) y que OrbiMed Advisors, GP VIII, OAP GP IV y Advisors IV tienen, de forma conjunta o individual, el poder de voto y dispositivo sobre dichas posiciones.
Los declarantes indican que las acciones fueron adquiridas con fines de inversión y no para obtener el control, y confirman que no tienen planes actuales para llevar a cabo transacciones extraordinarias ni cambios en el consejo. La presentación también resume un Amended and Restated Investors' Rights Agreement que otorga derechos de registro a petición (solicitudes de registro S-1 superiores a $20 million), derechos de registro en Form S-3 (umbrales que incluyen $5 million y ciertos titulares porcentuales) y derechos de registro piggyback, y señala que el director Carl L. Gordon forma parte del consejo y puede recibir premios en acciones sujetos a obligaciones de transferencia a las entidades de OrbiMed.
OrbiMed는 ArriVent BioPharma 보통주와 관련하여 Schedule 13D에 대한 Amendment No. 1을 제출하여 유통 주식 수 증가 후 실소유 지분 변동을 신고했습니다. 해당 수정서에는 총 3,027,328주의 집합적 유익소유권이 공개되어 있으며 이는 ArriVent 분기보고서에 기재된 40,568,944주 중 약 7.5%에 해당합니다. 제출서류는 OrbiMed Private Investments VIII, LP와 OrbiMed Asia Partners IV, L.P.가 각각 1,513,664주(각 약 3.7%)를 보유하고 있으며 OrbiMed Advisors, GP VIII, OAP GP IV 및 Advisors IV가 해당 지분에 대해 공동 또는 단독의 의결권 및 처분권을 보유한다고 명시합니다.
신고인들은 주식이 지배권 획득을 위한 것이 아니라 투자 목적을 위해 취득되었으며 현재 특별 거래나 이사회 변경을 추진할 계획이 없음을 밝혔습니다. 또한 수정·재작성된 투자자 권리계약(Amended and Restated Investors' Rights Agreement)을 요약하여, 수요 등록 권리(등록 요청이 $20 million을 초과하는 S-1 등록), Form S-3 등록 권리(기준에는 $5 million 및 특정 비율 보유자가 포함됨) 및 피기백(piggyback) 등록 권리를 제공하며, 이사인 Carl L. Gordon이 이사회 구성원으로서 OrbiMed 계열사에 대한 양도 의무가 적용되는 주식보상을 받을 수 있음을 기재했습니다.
OrbiMed a déposé l'Amendement n°1 à son Schedule 13D concernant les actions ordinaires d'ArriVent BioPharma afin de déclarer un changement de participation bénéficiaire après une augmentation des actions en circulation. L'amendement révèle une participation bénéficiaire agrégée de 3,027,328 actions, représentant environ 7.5% des 40,568,944 actions en circulation mentionnées dans le Quarterly Report d'ArriVent. Le dépôt précise que OrbiMed Private Investments VIII, LP et OrbiMed Asia Partners IV, L.P. détiennent chacune 1,513,664 actions (environ 3,7% chacune) et que OrbiMed Advisors, GP VIII, OAP GP IV et Advisors IV exercent, conjointement ou individuellement, le pouvoir de vote et le pouvoir de disposition sur ces positions.
Les déclarants indiquent que les actions ont été acquises à des fins d'investissement et non pour obtenir le contrôle, et confirment qu'ils n'ont pas de projets actuels visant des opérations extraordinaires ou des modifications du conseil d'administration. Le dossier résume également un Amended and Restated Investors' Rights Agreement qui prévoit des droits d'enregistrement sur demande (demandes d'enregistrement S-1 supérieures à $20 million), des droits d'enregistrement sur formulaire S-3 (seuils incluant $5 million et certains détenteurs en pourcentage) et des droits d'enregistrement piggyback, et note que l'administrateur Carl L. Gordon est membre du conseil et peut recevoir des attributions d'actions soumises à des obligations de transfert envers les entités OrbiMed.
OrbiMed hat Nachtrag Nr. 1 zu seinem Schedule 13D bezüglich der Stammaktien von ArriVent BioPharma eingereicht, um eine Änderung der wirtschaftlichen Eigentumsverhältnisse nach einer Erhöhung der ausstehenden Aktien zu melden. Die Änderung offenbart eine aggregierte wirtschaftliche Eigentümerschaft von 3,027,328 Aktien, was rund 7.5% der in ArriVents Quartalsbericht genannten 40,568,944 ausstehenden Aktien entspricht. Die Einreichung stellt klar, dass OrbiMed Private Investments VIII, LP und OrbiMed Asia Partners IV, L.P. jeweils 1,513,664 Aktien (jeweils etwa 3,7%) halten und dass OrbiMed Advisors, GP VIII, OAP GP IV und Advisors IV über diese Positionen gemeinschaftlich oder allein Stimm- und Verfügungsgewalt besitzen.
Die meldenden Personen geben an, dass die Aktien zu Anlagezwecken und nicht zur Erlangung von Kontrolle erworben wurden, und bestätigen, dass sie derzeit keine Pläne für außergewöhnliche Transaktionen oder Änderungen im Vorstand verfolgen. Die Einreichung fasst zudem ein Amended and Restated Investors' Rights Agreement zusammen, das Anmeldeansprüche auf Verlangen (S-1-Anmeldungen über $20 million), Form S-3-Anmeldeberechtigungen (Schwellen, einschließlich $5 million und bestimmte Prozentinhaber) sowie Mitregistrierungsrechte (piggyback) vorsieht, und weist darauf hin, dass der Direktor Carl L. Gordon Vorstandsmitglied ist und möglicherweise Aktienzuteilungen erhält, die Übertragungsverpflichtungen gegenüber den OrbiMed-Einheiten unterliegen.
- Clear disclosure of aggregate holdings: 3,027,328 shares representing approximately 7.5% of outstanding shares (40,568,944).
- Investors' Rights Agreement provides demand registration, Form S-3 and piggyback registration rights, preserving liquidity options for holders.
- Affiliation and control mechanics are documented, including which entities hold voting and dispositive power, improving transparency.
- Ownership percentage declined by >1% due to an increase in shares outstanding, indicating dilution of OrbiMed's stake.
- Reporting Persons may have ability to affect control because Carl L. Gordon is a director and certain contractual transfer obligations exist, which could raise governance attention for some investors.
Insights
TL;DR: OrbiMed reports a combined 7.5% stake in ArriVent after dilution; filing reiterates investment intent and registration rights.
The Schedule 13D/A provides precise holdings data and explains the mechanics behind the reported decrease in ownership: an increase in the issuer's share count reduced OrbiMed's percentage ownership by more than 1%. The filing identifies the specific entities and vote/disposition arrangements, clarifying that 1,513,664 shares are attributable to each of OPI VIII and OAP IV and that OrbiMed Advisors may be deemed to control 3,027,328 shares in the aggregate. The Investors' Rights Agreement provisions are spelled out, including demand registration thresholds and Form S-3 and piggyback rights, which preserve liquidity and exit optionality for these holders. No new strategic intentions or control actions are disclosed.
TL;DR: Transparent disclosure of ownership, affiliations, and director relationships; no declared plans to change governance or pursue control.
The amendment responsibly documents relationships among OrbiMed entities and the board connection via Carl L. Gordon, noting his role as a director and the contractual obligation to transfer any director equity awards to the OrbiMed entities. This disclosure is material for governance assessment because it clarifies potential influence while explicitly stating the Reporting Persons did not acquire shares to effect control and have no current plans to alter board composition or pursue extraordinary corporate actions. Investors gain clearer visibility into voting and disposition power and the existence of registration rights that affect potential monetization timelines.
OrbiMed ha presentato l'Amendment No. 1 al proprio Schedule 13D relativo alle azioni ordinarie di ArriVent BioPharma per segnalare una variazione nella proprietà effettiva a seguito dell'aumento delle azioni in circolazione. L'emendamento dichiara una titolarità aggregata di 3,027,328 azioni, pari a circa 7.5% delle 40,568,944 azioni in circolazione indicate nel Quarterly Report di ArriVent. Il documento chiarisce che OrbiMed Private Investments VIII, LP e OrbiMed Asia Partners IV, L.P. detengono ciascuna 1,513,664 azioni (circa il 3,7% ciascuna) e che OrbiMed Advisors, GP VIII, OAP GP IV e Advisors IV esercitano congiuntamente o individualmente potere di voto e di disposizione su tali posizioni.
I dichiaranti affermano che le azioni sono state acquistate per fini di investimento e non per acquisire il controllo, e confermano di non avere piani attuali per operazioni straordinarie o cambiamenti nel consiglio di amministrazione. L'atto riassume inoltre un Amended and Restated Investors' Rights Agreement che prevede diritti di registrazione su richiesta (richieste di registrazione S-1 superiori a $20 million), diritti di registrazione su Form S-3 (soglie che includono $5 million e detentori con determinate percentuali) e diritti di registrazione piggyback, e nota che il direttore Carl L. Gordon è membro del consiglio e potrà ricevere assegnazioni azionarie soggette a obblighi di trasferimento verso le entità OrbiMed.
OrbiMed presentó la Enmienda nº 1 a su Schedule 13D relativa a las acciones ordinarias de ArriVent BioPharma para informar un cambio en la propiedad efectiva tras un aumento en las acciones en circulación. La enmienda declara una participación agregada de 3,027,328 acciones, que representa aproximadamente el 7.5% de las 40,568,944 acciones en circulación informadas en el Quarterly Report de ArriVent. El documento aclara que OrbiMed Private Investments VIII, LP y OrbiMed Asia Partners IV, L.P. poseen cada una 1,513,664 acciones (aprox. 3,7% cada una) y que OrbiMed Advisors, GP VIII, OAP GP IV y Advisors IV tienen, de forma conjunta o individual, el poder de voto y dispositivo sobre dichas posiciones.
Los declarantes indican que las acciones fueron adquiridas con fines de inversión y no para obtener el control, y confirman que no tienen planes actuales para llevar a cabo transacciones extraordinarias ni cambios en el consejo. La presentación también resume un Amended and Restated Investors' Rights Agreement que otorga derechos de registro a petición (solicitudes de registro S-1 superiores a $20 million), derechos de registro en Form S-3 (umbrales que incluyen $5 million y ciertos titulares porcentuales) y derechos de registro piggyback, y señala que el director Carl L. Gordon forma parte del consejo y puede recibir premios en acciones sujetos a obligaciones de transferencia a las entidades de OrbiMed.
OrbiMed는 ArriVent BioPharma 보통주와 관련하여 Schedule 13D에 대한 Amendment No. 1을 제출하여 유통 주식 수 증가 후 실소유 지분 변동을 신고했습니다. 해당 수정서에는 총 3,027,328주의 집합적 유익소유권이 공개되어 있으며 이는 ArriVent 분기보고서에 기재된 40,568,944주 중 약 7.5%에 해당합니다. 제출서류는 OrbiMed Private Investments VIII, LP와 OrbiMed Asia Partners IV, L.P.가 각각 1,513,664주(각 약 3.7%)를 보유하고 있으며 OrbiMed Advisors, GP VIII, OAP GP IV 및 Advisors IV가 해당 지분에 대해 공동 또는 단독의 의결권 및 처분권을 보유한다고 명시합니다.
신고인들은 주식이 지배권 획득을 위한 것이 아니라 투자 목적을 위해 취득되었으며 현재 특별 거래나 이사회 변경을 추진할 계획이 없음을 밝혔습니다. 또한 수정·재작성된 투자자 권리계약(Amended and Restated Investors' Rights Agreement)을 요약하여, 수요 등록 권리(등록 요청이 $20 million을 초과하는 S-1 등록), Form S-3 등록 권리(기준에는 $5 million 및 특정 비율 보유자가 포함됨) 및 피기백(piggyback) 등록 권리를 제공하며, 이사인 Carl L. Gordon이 이사회 구성원으로서 OrbiMed 계열사에 대한 양도 의무가 적용되는 주식보상을 받을 수 있음을 기재했습니다.
OrbiMed a déposé l'Amendement n°1 à son Schedule 13D concernant les actions ordinaires d'ArriVent BioPharma afin de déclarer un changement de participation bénéficiaire après une augmentation des actions en circulation. L'amendement révèle une participation bénéficiaire agrégée de 3,027,328 actions, représentant environ 7.5% des 40,568,944 actions en circulation mentionnées dans le Quarterly Report d'ArriVent. Le dépôt précise que OrbiMed Private Investments VIII, LP et OrbiMed Asia Partners IV, L.P. détiennent chacune 1,513,664 actions (environ 3,7% chacune) et que OrbiMed Advisors, GP VIII, OAP GP IV et Advisors IV exercent, conjointement ou individuellement, le pouvoir de vote et le pouvoir de disposition sur ces positions.
Les déclarants indiquent que les actions ont été acquises à des fins d'investissement et non pour obtenir le contrôle, et confirment qu'ils n'ont pas de projets actuels visant des opérations extraordinaires ou des modifications du conseil d'administration. Le dossier résume également un Amended and Restated Investors' Rights Agreement qui prévoit des droits d'enregistrement sur demande (demandes d'enregistrement S-1 supérieures à $20 million), des droits d'enregistrement sur formulaire S-3 (seuils incluant $5 million et certains détenteurs en pourcentage) et des droits d'enregistrement piggyback, et note que l'administrateur Carl L. Gordon est membre du conseil et peut recevoir des attributions d'actions soumises à des obligations de transfert envers les entités OrbiMed.
OrbiMed hat Nachtrag Nr. 1 zu seinem Schedule 13D bezüglich der Stammaktien von ArriVent BioPharma eingereicht, um eine Änderung der wirtschaftlichen Eigentumsverhältnisse nach einer Erhöhung der ausstehenden Aktien zu melden. Die Änderung offenbart eine aggregierte wirtschaftliche Eigentümerschaft von 3,027,328 Aktien, was rund 7.5% der in ArriVents Quartalsbericht genannten 40,568,944 ausstehenden Aktien entspricht. Die Einreichung stellt klar, dass OrbiMed Private Investments VIII, LP und OrbiMed Asia Partners IV, L.P. jeweils 1,513,664 Aktien (jeweils etwa 3,7%) halten und dass OrbiMed Advisors, GP VIII, OAP GP IV und Advisors IV über diese Positionen gemeinschaftlich oder allein Stimm- und Verfügungsgewalt besitzen.
Die meldenden Personen geben an, dass die Aktien zu Anlagezwecken und nicht zur Erlangung von Kontrolle erworben wurden, und bestätigen, dass sie derzeit keine Pläne für außergewöhnliche Transaktionen oder Änderungen im Vorstand verfolgen. Die Einreichung fasst zudem ein Amended and Restated Investors' Rights Agreement zusammen, das Anmeldeansprüche auf Verlangen (S-1-Anmeldungen über $20 million), Form S-3-Anmeldeberechtigungen (Schwellen, einschließlich $5 million und bestimmte Prozentinhaber) sowie Mitregistrierungsrechte (piggyback) vorsieht, und weist darauf hin, dass der Direktor Carl L. Gordon Vorstandsmitglied ist und möglicherweise Aktienzuteilungen erhält, die Übertragungsverpflichtungen gegenüber den OrbiMed-Einheiten unterliegen.